Bimekizumab Efficacy and Safety through Two Years in Patients With Moderate Psoriasis: Analysis of Pooled Data from Five Phase 3 3b Clinical Trials. J of Skin 2022, 6 (6), s67. https://doi.org/10.25251/skin.6.supp.67.